Results for the substance belzutifan

Belzutifan is a medication used in the treatment of certain types of cancer, such as clear cell renal carcinoma, especially in patients with specific genetic mutations. It works by inhibiting a protein called HIF-2α, which plays a role in tumor growth and the survival of cancer cells in low-oxygen environments.

The medication is taken orally as tablets, following the oncologist’s prescription. The dose is adjusted individually based on the patient’s health status and response to therapy. Treatment is usually long-term and requires regular monitoring.

Common side effects include fatigue, headaches, nausea, anemia, and low blood oxygen levels. In some cases, more serious effects may occur, such as liver dysfunction or blood pressure changes, making regular medical check-ups necessary.

Belzutifan is a modern and promising option for treating rare genetic cancers, but its use requires close medical supervision to manage potential side effects and ensure treatment effectiveness.